Case Number:

IPR2021-00528

Case Type:

IPR

Status:

Terminated

Petitioner:

Pfizer Inc.

Patent Owner:

Amgen Inc

Tech Center:

1600

1. Filed: February 10, 2021 00:00

   Coverage

   1. August 18, 2021

      Pfizer Gets PTAB To Review Neulasta Patent In Amgen IP Row

      The Patent Trial and Appeal Board has agreed to review an Amgen patent covering its blockbuster anti-infection drug Neulasta in a challenge brought by Pfizer and Hospira, rejecting Amgen's argument that the board should deny inter partes review based on the state of parallel litigation in Delaware.

   ---

   Stay ahead of the curve

   In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

   
   

   • Search PTAB cases and full-text documents.
   • Download filings with the U.S. Patent & Trademark Office’s Patent Trial & Appeal Board.
   • Set up alerts on new cases, follow ongoing cases, track new decisions and so much more!

   TRY LAW360 FREE FOR SEVEN DAYS

   View the PTAB case documents

   Already a subscriber? Click here to login